The healthcare and life sciences sector is facing new trade winds and a looming threat of increased tariffs. This places additional pressure on a typical life sciences supply chain timeline.
We recently launched a four-part article series on supply chains, aimed at exploring the legal and operational complexities that healthcare and life sciences companies face as they navigate evolving global supply chain challenges.
The first article explores the steps companies can take to ensure business continuity in the face of disruption is available, and it explores the following key questions:
- How can strong supply agreements lower my risk exposure?
- Why should I pay attention to Excuse of Performance provisions?
- How can I protect my supply chain when working with CDMOs?
- How can I mitigate the impact of tariffs on my M&A?
Please watch out for the articles to follow.
